Zevin Asset Management LLC Grows Stock Position in AbbVie Inc. $ABBV

Zevin Asset Management LLC increased its position in shares of AbbVie Inc. (NYSE:ABBV) by 12.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 91,642 shares of the company’s stock after purchasing an additional 10,144 shares during the quarter. AbbVie makes up approximately 2.4% of Zevin Asset Management LLC’s investment portfolio, making the stock its 15th largest position. Zevin Asset Management LLC’s holdings in AbbVie were worth $17,011,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Marshall & Sullivan Inc. WA acquired a new stake in shares of AbbVie in the second quarter valued at about $25,000. TD Capital Management LLC boosted its stake in AbbVie by 82.9% during the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the last quarter. Spurstone Advisory Services LLC acquired a new stake in AbbVie during the second quarter worth about $28,000. Cypress Capital Management LLC WY acquired a new stake in shares of AbbVie during the 1st quarter worth approximately $35,000. Finally, Bear Mountain Capital Inc. increased its stake in AbbVie by 480.6% during the second quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of research reports. HSBC set a $225.00 price objective on shares of AbbVie in a report on Thursday, October 2nd. Bank of America boosted their target price on AbbVie from $220.00 to $251.00 and gave the stock a “neutral” rating in a research note on Friday, October 3rd. JPMorgan Chase & Co. lifted their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Finally, BMO Capital Markets lifted their price objective on shares of AbbVie from $215.00 to $240.00 and gave the company an “outperform” rating in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $238.05.

Insider Transactions at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total transaction of $8,407,055.40. Following the completion of the transaction, the executive vice president owned 177,292 shares of the company’s stock, valued at approximately $35,178,278.64. This represents a 19.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.25% of the company’s stock.

AbbVie Trading Down 0.1%

Shares of ABBV stock opened at $218.82 on Friday. The company has a quick ratio of 0.61, a current ratio of 0.74 and a debt-to-equity ratio of 44.14. The stock has a market cap of $386.55 billion, a P/E ratio of 103.85, a P/E/G ratio of 1.42 and a beta of 0.50. The business has a fifty day simple moving average of $223.06 and a 200-day simple moving average of $201.96. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. The company’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the prior year, the business earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.